Guides On Our Expedition: Introducing Our Scientific Advisory Board

We’re excited to announce the formation of the Scientific Advisory Board for Expedition Medicines.

As a company building a platform for the generative design of covalent drugs, we’re keenly aware that our progress depends on learning from the experts who have spent decades pushing the boundaries of science and drug discovery.

Our new SAB brings deep, complementary expertise that will help shape our scientific direction and keep our work grounded in what ultimately matters: designing new small molecule medicines that stand up to reality at the bench and in the clinic.

• Chris Bishop, PhD Technical Fellow and founder of Microsoft Research AI for Science, joins the board with deep expertise in scaling compute and building high-accuracy synthetic quantum chemistry models. His perspective is tightly aligned with Expedition’s effort to pair a proteome-wide, billion-plus dataset of covalent protein – ligand interactions with generative AI grounded in the quantum chemistry of electron densities and orbitals.
• Joel Barrish, PhD Venture Partner at RA Ventures, brings more than four decades of leadership in small-molecule drug discovery across pharma and biotech, including guiding the creation and acquisition of Jnana Therapeutics, an early proteomics-driven platform company. His experience translating platform science into disease-focused medicines will be invaluable as Expedition advances its own discovery engine toward real therapeutic impact.
• Don Payan, MD, contributes a combination of clinical training, deep biological insight, and firsthand experience founding and scaling drug discovery companies across immunology, oncology, and metabolic disease. His background — from academic medicine to leading multiple biotech ventures — offers a pragmatic lens on how innovative discovery paradigms can be developed into robust pipelines.
• Steve Gygi, PhD, Professor at Harvard University, is a pioneer of modern proteomics whose work in mass spectrometry and chemoproteomics has fundamentally shaped how proteins are measured at scale. His guidance will be critical as Expedition continues to build a proteomics-driven foundation for covalent drug design.

We’re excited to welcome these outstanding scientists to our SAB.